PT  - JOURNAL ARTICLE
AU  - Kany, Shinwan
AU  - Rämö, Joel T.
AU  - Hou, Cody
AU  - Jurgens, Sean J.
AU  - Nauffal, Victor
AU  - Cunningham, Jon
AU  - Lau, Emily S.
AU  - Butte, Atul J.
AU  - Ho, Jennifer E.
AU  - Olgin, Jeffrey E.
AU  - Elmariah, Sammy
AU  - Lindsay, Mark E.
AU  - Ellinor, Patrick T.
AU  - Pirruccello, James P.
TI  - Assessment of valvular function in over 47,000 people using deep learning-based flow measurements
AID  - 10.1101/2023.04.29.23289299
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.04.29.23289299
4099  - http://medrxiv.org/content/early/2023/05/01/2023.04.29.23289299.short
4100  - http://medrxiv.org/content/early/2023/05/01/2023.04.29.23289299.full
AB  - Valvular heart disease is associated with a high global burden of disease. Even mild aortic stenosis confers increased morbidity and mortality, prompting interest in understanding normal variation in valvular function at scale.We developed a deep learning model to study velocity-encoded magnetic resonance imaging in 47,223 UK Biobank participants. We calculated eight traits, including peak velocity, mean gradient, aortic valve area, forward stroke volume, mitral and aortic regurgitant volume, greatest average velocity, and ascending aortic diameter. We then computed sex-stratified reference ranges for these phenotypes in up to 31,909 healthy individuals. In healthy individuals, we found an annual decrement of 0.03cm2 in the aortic valve area. Participants with mitral valve prolapse had a 1 standard deviation [SD] higher mitral regurgitant volume (P=9.6 × 10−12), and those with aortic stenosis had a 4.5 SD-higher mean gradient (P=1.5 × 10−431), validating the derived phenotypes’ associations with clinical disease. Greater levels of ApoB, triglycerides, and Lp(a) assayed nearly 10 years prior to imaging were associated with higher gradients across the aortic valve. Metabolomic profiles revealed that increased glycoprotein acetyls were also associated with an increased aortic valve mean gradient (0.92 SD, P=2.1 x 10−22). Finally, velocity-derived phenotypes were risk markers for aortic and mitral valve surgery even at thresholds below what is considered relevant disease currently.Using machine learning to quantify the rich phenotypic data of the UK Biobank, we report the largest assessment of valvular function and cardiovascular disease in the general population.Competing Interest StatementDr. Lau reports previous modest honoraria from Roche Diagnostics. Dr. Ho has received research support from Bayer AG. Dr. Ellinor is supported by a grant from Bayer AG to the Broad Institute focused on the genetics and therapeutics of cardiovascular diseases. Dr. Ellinor receives sponsored research support from Bayer AG, IBM Research, Bristol Myers Squibb and Pfizer; he has also served on advisory boards or consulted for Bayer AG, MyoKardia and Novartis. Dr. Lindsay receives sponsored research support from Angea Biotherapeutics. Remaining authors report no disclosures.Funding StatementDr. Kany was supported by the Walter Benjamin Fellowship from the Deutsche Forschungsgemeinschaft (521832260). Dr. Ramo was supported by a research fellowship from the Sigrid Juselius Foundation. Dr. Nauffal is supported by NIH grant 5T32HL007604-35. Dr. Khurshid is supported by NIH grant T32HL007208. This work was supported by grants from the National Institutes of Health to Dr. Lau (K23-HL159243), Dr. Ellinor (11R01HL092577, 1R01HL157635, 5R01HL139731), Dr. Ho (R01HL134893, R01HL140224, R01HL160003, K24HL153669), and Dr. Pirruccello (K08HL159346). This work was also supported by grants to Dr. Lau from the American Heart Association (853922), Dr. Ellinor from the American Heart Association Strategically Focused Research Networks (18SFRN34110082), and from the European Union (MAESTRIA 965286). Dr. Lindsay is supported by the Toomey Fund for Aortic Dissection Research and by NIH grant (1R01NS125353).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project was conducted under UK Biobank application #41664. It was approved by the Mass General Brigham institutional review board (IRB; protocol 2019P003144) and considered exempt by the University of California San Francisco IRB (#22-37715).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe derived phenotypes from application #41664 will be returned to the UK Biobank. Access to UK Biobank data may be requested by researchers in academic, commercial, and charitable organizations.